

Rami S. Komrokji, MD

Professor of Medicine and Oncologic Sciences
University of South Florida College of Medicine
Vice Chair, Malignant Hematology Department
Moffitt Cancer Center
Tampa, Florida

I'm Dr. Rami Komrokji from Moffitt Cancer Center answering the following question related to myeloproliferative neoplasms.

Where does fedratinib fit in the treatment option for myelofibrosis?

For patients that experience ruxolitinib failure, that's definitely an option. Ruxolitinib failure is defined usually as having at least three months of adequate trial of the ruxolitinib and failure to have spleen reduction or symptom improvement, or if patients had the response, losing that response. Intolerance is defined with having at least one month of ruxolitinib and developing cytopenias that require transfusions. So in that setting, around 30% of the patients did benefit from fedratinib.